BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29251321)

  • 1. Antitumor potential of a novel camptothecin derivative, ZBH-ZM-06.
    Wu D; Zhao DW; Li YQ; Shi WG; Yin QL; Tu ZK; Yu YY; Zhong BH; Yu H; Bao WG
    Oncol Rep; 2018 Feb; 39(2):871-879. PubMed ID: 29251321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the chemotherapeutic potential of a new camptothecin derivative, ZBH-1205.
    Wu D; Shi W; Zhao J; Wei Z; Chen Z; Zhao D; Lan S; Tai J; Zhong B; Yu H
    Arch Biochem Biophys; 2016 Aug; 604():74-85. PubMed ID: 27302903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel irinotecan derivative ZBH-1207 with different anti-tumor mechanism from CPT-11 against colon cancer cells.
    Zhao D; Wu D; Zhang G; Li Y; Shi W; Zhong B; Yu H
    Mol Biol Rep; 2022 Sep; 49(9):8359-8368. PubMed ID: 35764749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel camptothecin derivative, ZBH-01, exhibits superior antitumor efficacy than irinotecan by regulating the cell cycle.
    Li Y; Zhao D; Zhang W; Yang M; Wu Z; Shi W; Lan S; Guo Z; Yu H; Wu D
    J Transl Med; 2023 Jun; 21(1):422. PubMed ID: 37386467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects.
    Du Y; Zhang W; He R; Ismail M; Ling L; Yao C; Fu Z; Li X
    Bioorg Med Chem; 2017 Jun; 25(12):3247-3258. PubMed ID: 28465086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-assembling nanowires of an amphiphilic camptothecin prodrug derived from homologous derivative conjugation.
    He D; Zhang W; Deng H; Huo S; Wang YF; Gong N; Deng L; Liang XJ; Dong A
    Chem Commun (Camb); 2016 Dec; 52(98):14145-14148. PubMed ID: 27869268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers.
    Zhao H; Rubio B; Sapra P; Wu D; Reddy P; Sai P; Martinez A; Gao Y; Lozanguiez Y; Longley C; Greenberger LM; Horak ID
    Bioconjug Chem; 2008 Apr; 19(4):849-59. PubMed ID: 18370417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatiotemporal Concurrent Liberation of Cytotoxins from Dual-Prodrug Nanomedicine for Synergistic Antitumor Therapy.
    Zhang L; Qian M; Cui H; Zeng S; Wang J; Chen Q
    ACS Appl Mater Interfaces; 2021 Feb; 13(5):6053-6068. PubMed ID: 33525873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11.
    Hyatt JL; Tsurkan L; Morton CL; Yoon KJ; Harel M; Brumshtein B; Silman I; Sussman JL; Wadkins RM; Potter PM
    Chem Biol Interact; 2005 Dec; 157-158():247-52. PubMed ID: 16257398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of a camptothecin prodrug with glutathione-responsive disulfide linker for anticancer drug delivery.
    Xu Z; Wang D; Xu S; Liu X; Zhang X; Zhang H
    Chem Asian J; 2014 Jan; 9(1):199-205. PubMed ID: 24136878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSMA-Oriented Target Delivery of Novel Anticancer Prodrugs: Design, Synthesis, and Biological Evaluations of Oligopeptide-Camptothecin Conjugates.
    Xu B; Zhou F; Yan MM; Cai DS; Guo WB; Yang YQ; Jia XH; Zhang WX; Li T; Ma T; Wang PL; Lei HM
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redox-responsive amphiphilic camptothecin prodrug nanoparticles for targeted liver tumor therapy.
    Lu L; Li B; Lin C; Li K; Liu G; Xia Z; Luo Z; Cai K
    J Mater Chem B; 2020 May; 8(17):3918-3928. PubMed ID: 32227058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.
    Yoon KJ; Krull EJ; Morton CL; Bornmann WG; Lee RE; Potter PM; Danks MK
    Mol Cancer Ther; 2003 Nov; 2(11):1171-81. PubMed ID: 14617791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity.
    Liu Y; Piao H; Gao Y; Xu C; Tian Y; Wang L; Liu J; Tang B; Zou M; Cheng G
    Int J Nanomedicine; 2015; 10():2295-311. PubMed ID: 25848251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and preliminary bioevaluation of novel E-ring modified acetal analog of camptothecin as cytotoxic agents.
    Zhu L; Zhuang C; Lei N; Guo Z; Sheng C; Dong G; Wang S; Zhang Y; Yao J; Miao Z; Zhang W
    Eur J Med Chem; 2012 Oct; 56():1-9. PubMed ID: 23084702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action.
    Harel M; Hyatt JL; Brumshtein B; Morton CL; Yoon KJ; Wadkins RM; Silman I; Sussman JL; Potter PM
    Mol Pharmacol; 2005 Jun; 67(6):1874-81. PubMed ID: 15772291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies.
    Zhang H; Wang J; Mao W; Huang J; Wu X; Shen Y; Sui M
    J Control Release; 2013 Mar; 166(2):147-58. PubMed ID: 23266448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supramolecular Crafting of Self-Assembling Camptothecin Prodrugs with Enhanced Efficacy against Primary Cancer Cells.
    Su H; Zhang P; Cheetham AG; Koo JM; Lin R; Masood A; Schiapparelli P; Quiñones-Hinojosa A; Cui H
    Theranostics; 2016; 6(7):1065-74. PubMed ID: 27217839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line.
    Arnould S; Guichard S; Hennebelle I; Cassar G; Bugat R; Canal P
    Biochem Pharmacol; 2002 Oct; 64(8):1215-26. PubMed ID: 12234602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
    Whitacre CM; Zborowska E; Willson JK; Berger NA
    Clin Cancer Res; 1999 Mar; 5(3):665-72. PubMed ID: 10100720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.